Mechanisms of malignant ascites production
- PMID: 2434730
- DOI: 10.1016/0022-4804(87)90109-0
Mechanisms of malignant ascites production
Abstract
The accumulation of malignant ascites is determined primarily by the obstruction of diaphragmatic lymphatics with tumor inhibiting the outflow of peritoneal fluid. An abnormal increase in peritoneal fluid production has been shown to contribute to ascites formation by a marked neovascularization of the parietal peritoneum. Cell-free malignant ascitic fluid obtained from rats with intra-abdominal Walker 256 carcinoma when infused into the peritoneal cavities of normal animals causes an increase in edema formation and an increase in the permeability of protein from normal omental vessels. Protamine sulfate, a known inhibitor of angiogenesis when infused into the peritoneal cavity along with cell free malignant ascitic fluid, significantly reduces the leak of protein from the intravascular space when compared to ascites alone. Persistent permeability changes continue to exist even after the inhibition of vessel proliferation. These results indicate that angiogenesis is responsible for a major portion of the increase in permeability caused by malignant ascitic fluids. Other tumor-induced factors may be present which alter vascular permeability by other mechanisms which remain to be elucidated.
Similar articles
-
Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis.J Surg Res. 1984 Mar;36(3):244-50. doi: 10.1016/0022-4804(84)90094-5. J Surg Res. 1984. PMID: 6199588
-
Malignant ascites. Clinical and experimental observations.Ann Surg. 1986 Jun;203(6):644-51. doi: 10.1097/00000658-198606000-00009. Ann Surg. 1986. PMID: 3718029 Free PMC article.
-
Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.Cancer Res. 1995 Jan 15;55(2):376-85. Cancer Res. 1995. PMID: 7529135
-
The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female.Gynecol Obstet Invest. 2000;50(4):217-24. doi: 10.1159/000010320. Gynecol Obstet Invest. 2000. PMID: 11093042 Review.
-
Lymphatic and nonlymphatic pathways of peritoneal absorption in mice: physiology versus pathology.Blood Purif. 1992;10(3-4):148-62. doi: 10.1159/000170042. Blood Purif. 1992. PMID: 1308681 Review.
Cited by
-
Diagnosis and treatment of bacterial peritonitis in patients with gastrointestinal cancer: an observational multicenter study.Ther Adv Med Oncol. 2024 Jun 5;16:17588359241258440. doi: 10.1177/17588359241258440. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38845791 Free PMC article.
-
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.Clin Pharmacol. 2013 Oct 3;5(Suppl 1):55-61. doi: 10.2147/CPAA.S45885. Clin Pharmacol. 2013. PMID: 24124397 Free PMC article. Review.
-
Tumor microenvironment in ovarian cancer peritoneal metastasis.Cancer Cell Int. 2023 Jan 25;23(1):11. doi: 10.1186/s12935-023-02854-5. Cancer Cell Int. 2023. PMID: 36698173 Free PMC article. Review.
-
Palliative treatment of malignant ascites: profile of catumaxomab.Biologics. 2010 May 25;4:103-10. doi: 10.2147/btt.s6697. Biologics. 2010. PMID: 20531969 Free PMC article.
-
Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.Int J Cancer. 2016 Oct 15;139(8):1788-98. doi: 10.1002/ijc.30209. Epub 2016 Jun 20. Int J Cancer. 2016. PMID: 27242346 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources